[Quantitative Decision Making in Drug Development: Pharmacometrics].
1Pfizer Japan Inc., Clinical Pharmacology.
Summary
Pharmacometrics quantifies drug development data for regulatory decisions. Model-based meta-analysis (MBMA) uses summary data to position drugs, despite treatment effect heterogeneity, and will be key in future drug development.
Area of Science:
- Pharmacometrics and drug development
- Quantitative decision-making in regulatory science
Background:
- Pharmacometrics, as defined by the US FDA, is a science focused on quantifying drugs, diseases, and trial data.
- Quantitative decision-making is integral throughout the drug development lifecycle.
- Patient-level data are typically proprietary, but summary-level data are accessible.
Purpose of the Study:
- To highlight the role of pharmacometrics in efficient drug development.
- To introduce Model-Based Meta-Analysis (MBMA) as a tool for market positioning.
- To discuss the utility and limitations of MBMA in drug development.
Main Methods:
- Utilizing summary-level data for analysis.
- Employing Model-Based Meta-Analysis (MBMA) for decision-making.
- Addressing heterogeneity in treatment effects within MBMA.
Main Results:
- MBMA is identified as a powerful tool for determining a drug's market position.
- Heterogeneity of treatment effect is a key limitation of MBMA.
- MBMA is expected to be applied across all stages of drug development in the future.
Conclusions:
- Pharmacometrics supports efficient drug development and regulatory decisions.
- MBMA offers valuable insights for market positioning using accessible data.
- Overcoming MBMA's limitations, particularly treatment effect heterogeneity, is crucial for its broader application.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
62
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
62
01:12Analysis of Population Pharmacokinetic Data
902
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
902
01:26Pharmacokinetic Models: Comparison and Selection Criterion
448
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
448
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
254
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
254
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
70
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
70
01:20Measurement of Bioavailability: Pharmacodynamic Methods
944
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
944